SPOCK1 and prostate cancer: Notably, clinical and pathological studies have demonstrated that SPOCK1 is frequently overexpressed in highly metastatic human prostate cancer tissues, thus it could be an attractive prognostic biomarker and therapeutic target in cancer treatment [44].